Updates are available Correction dated 2025-12-19

Article History

Received: 20 March 2025

Accepted: 26 June 2025

First Online: 14 July 2025

Change Date: 7 December 2025

Change Type: Update

Change Details: The original online version of this article was revised to amend references 30 to 45 and the in-text citation of supplementary material 6.

Change Date: 19 December 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s10120-025-01697-5

Declarations

:

: DC reports research funding from Clovis, Eli Lilly, 4SC, Leap, and Roche. IC reports the advisory boards for Bristol Myers Squibb, AstraZeneca, OncXerna, Astellas, GSK, Eisai, Daiichi-Sankyo, Taiho, Servier, Seagen, BioNTech, Novartis, Takeda, Elevation Oncology, Beigene, and Jazz Pharmaceuticals and has received research funding from Eli Lilly and Janssen-Cilag and honoraria from Eli Lilly, Eisai, Servier, Roche, BMS, Jazz Pharmaceuticals, Astellas, and Roche. NS reports serving on the advisory boards of AstraZeneca, MSD Oncology, Novartis, Guardant, GSK, Gilead, Seagen, Janssen, Takeda, Moderna, and BMS; research funding from AstraZeneca, BMS, Guardant, and Gilead; and honoraria from Merck, Novartis, Amgen, Eli Lilly, GSK, Servier, Pierre Fabre, Seagen, MSD Oncology, BMS, AstraZeneca, Astellas, and Guardant. SR receives financial support from Boehringer, Merck, Servier, and Bayer; has served on advisory boards for HOOKIPA, Bayer, Beigene, AstraZeneca, Merck, Seagen, and Servier. The remaining authors declare no conflicts of interest. The other authors declare no conflicts of interest.